Nanchang, Jiangxi, China – September 7, 2026 – What you think is a “standby option” is actually something that can be discarded at any time.

Let us first shed light on the cost considerations for pharmaceutical formulation clients.

In the European and American markets, production costs (COGS) account for 40%–60% of the ex-factory price of a generic drug. Within this cost component, active pharmaceutical ingredients (APIs) dominate absolutely (>50%), while excipients, packaging materials, labor costs, and depreciation combined account for only approximately 30%.

These 30% represent what I often refer to as “production switching costs.”

Its low price isn’t due to lack of importance, but rather because the API is too expensive.https://www.jxserum.com/apis-intermediates/

And this is precisely the fundamental reason why customers feel confident enough to abandon you at any time.

Suppose a customer’s warehouse has finished goods inventory worth 10 million yuan and uses your API. When they want to switch to a new supplier that costs 15% less:

cost structure	amount of money	Customer Psychology
API prime cost	7 million	It has already happened; sunk costs.
conversion cost	3 million	Excipients, labor costs, depreciation, etc.
Decision Result	exchange ！	The only losses are minor expenses for auxiliary materials and labor costs—nothing serious.

This is the harsh reality:

Low conversion costs aren’t your advantage as a secondary supplier; they’re the root cause of your inability to secure long-term commitments. There’s no bond between you and your customers—only a fragile thread that could snap at any moment.

Second, what truly prevents customers from making a purchase are these three major obstacles.

The conversion cost is merely a psychological barrier. What truly compels customers to carefully weigh their options when considering a second supplier are three critical financial considerations that require substantial capital and scarce resources to address.

1. Hard investment: A “entry fee” of $500,000–$1 million

When introducing new API suppliers, pharmaceutical manufacturers must incur significant costs that cannot be avoided.

Quality comparison study: A comprehensive element-by-element comparison between the old and new APIs. For processes that are similar, the cost ranges from $100,000 to $200,000; for processes that differ, the analytical methods must be redone, resulting in costs easily exceeding $300,000.

Process validation: Three consecutive batches on the commercial production line required validation, consuming production capacity and materials at a cost of $150,000–$250,000.

Stability study: accelerated and long-term evaluation over 6 months, cost ranging from $50,000 to $150,000.

Registration submission and auditing: FDA’s PAS applications, DMF reviews, and GMP audits, costing between $180,000 and $300,000.

Total: $480,000 – $1,000,000.

If the production processes differ, this figure will double. Customers must calculate the ROI: if the annual savings on procurement costs cannot cover the investment within three years, the project simply won’t succeed.

2. Time cost: An underestimated hidden killer

The primary supplier is still delivering supplies normally – can’t we gradually introduce them?

No. This is because the people making changes are the same as those generating revenue from production.

The R&D, quality control, and regulatory registration teams at pharmaceutical manufacturers suffer from severe resource shortages. When these teams are deployed to handle “standby projects,” they become unable to advance the application process for the next generic drug candidate.

There is a critical time window here:

In the United States, first-to-market generic drugs enjoy an exclusive market period of 180 days. The profits generated during this 180-day period can account for 60% to 80% of a drug’s total lifetime revenue.

The time cost of introducing a second supplier doesn’t delay current sales, but means missing the opportunity to leverage the same team to capture the next 180-day golden window.

3. Management costs: The persistent pain of ongoing financial loss

Once a second supplier is introduced, ongoing management costs begin to accumulate:

Two sets of quality standards, two material codes, two sets of inspection SOPs, and two annual audits—all these factors have led to a sharp increase in the workload and error risks for supply chain and quality departments. The internal resistance is far greater than outsiders might imagine.

3. By understanding this model, you’ll grasp the logic behind share allocation.

When evaluating suppliers for a newly approved first-in-class generic drug manufacturer, the focus is not on determining “which API is superior,” but rather on solving a complex equation involving financial, time, risk, and management costs.

Want to become a secondary supplier? You need to reduce prices by 10%-15%.

This coverage level is designed to cover the customer’s total management costs, ensuring they feel that “this insurance policy is worth the price.”

Want to become a third-party supplier? You need to reduce prices by 20%–30%, or even more.

Your incremental security value is virtually zero; customers will only pay for the “extreme cost advantage.” Your ultra-low price essentially acts as a “catfish,” designed to pressure the top two competitors during annual price negotiations.

Conclusion: A true competitive moat lies in being “irreplaceable”.

The cruel reality of this industry is:

By merely ensuring consistent quality at lower prices, you’ll remain nothing more than a disposable replacement part.

A true competitive advantage must lead customers to reach the same conclusion after evaluating all the factors involved:https://www.jxserum.com/apis-intermediates/

“Replacing him would be too expensive.”

This “high cost” doesn’t refer to expensive APIs, but rather to exorbitant time investments, regulatory risks, management efforts, and sunk costs.

The key to achieving this isn’t simply being slightly better than others at a single point, but rather:

✅Ensure your workflow is highly compatible with the customer ecosystem

✅Make your supply chain absolutely reliable.

✅Make your file management system completely hassle-free for the registration department

In the competitive landscape of generic drugs, pricing power never favors the most effective alternatives—it always favors those that are hardest to replace.

You’ve done an excellent job—you’re the engine your customers simply can’t bear to replace.

If you don’t perform well, you’re just that tire that can be replaced at any time.

About Us

Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly ten years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.

Media Contact
Company Name: Jiangxi Serum Pharma Industries Co., Ltd.
Contact Person: Media Relations
Email: Send Email
Country: China
Website: https://www.jxserum.com/